For patients with centrifugal flow left ventricular assist devices (LVADs), postimplant use of phosphodiesterase-5 inhibitors (PDE-5i) decreased risk for mortality and ischemic stroke. These findings were published in JACC: Heart Failure.

Data for this study were sourced from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database. Patients (N=7229) who received a primary continuous flow centrifugal LVAD between 2017 and 2020 were assessed for outcomes on the basis of receiving postimplant PDE-5i. The primary endpoint was the composite outcome of pump thrombosis, ischemic stroke, and all-cause mortality.

Patients were aged mean 57.2±13.0 years, 77.1% were men, 28.5% were Black, BMI was 28.8±7.2 kg/m2, and time on LVAD was 11.91±8.60 months. Patients who received PDE-5i (30.1%) were younger, more were Black, fewer smoked, more received a Heartware HVAD device, they had higher preimplant international normalized ratio, more pulmonary hypertension, and were more likely to have history of renal disease.


Continue Reading

The composite endpoint occurred among 18.9% of the PDE-5i and 21.2% of the no PDE-5i cohorts (adjusted hazard ratio [aHR], 0.77; 95% CI, 0.69-0.86; P <.0001).

Stratified by outcome components, PDE-5i was associated with decreased risk for all-cause mortality (aHR, 0.75; 95% CI, 0.65-0.86; P <.0001) and ischemic stroke (aHR, 0.71; 95% CI, 0.56-0.89; P =.003) but not for pump thrombosis (aHR, 1.01; 95% CI, 0.77-1.32; P =.934).

Stratified by implanted device, PDE-5i was associated with decreased risk for the composite outcome for both Heartware HVAD (aHR, 0.76; 95% CI, 0.66-0.88; P =.0002) and HeartMate 3 (aHR, 0.77; 95% CI, 0.64-0.92; P =.0044) devices. Similar results were observed for all-cause mortality (both P ≤.0098) and ischemic stroke (both P ≤.045).

In subgroup analyses, PDE-5i was favored for younger (<60 years) and older (³60 years) patients (HR range, 0.75-0.78; P ≤.03), men (HR, 0.75; P <.001), White patients (HR, 0.75; P <.001), both types of LVAD (HR range, 0.69-0.80; P ≤.016), all device strategies (HR range, 0.58-0.81; P ≤.021), and any pulmonary hypertension status (HR range, 0.69-0.78; P ≤.031). For women and Black patients, PDE-5i tended to be favored.

This study was limited by not having sufficient data to account for dosage or duration of therapy.

“The adjunctive use of PDE-5is after LVAD might result in incremental improvement with contemporary LVAD technology,” the researchers noted. “A randomized controlled trial is necessary to determine the efficacy and safety with PDE-5i use postimplant of a centrifugal flow LVAD.”

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.

Reference

Xanthopoulos A, Wolski K, Wang Q, et al. Postimplant phosphodiesterase-5 inhibitor use in centrifugal flow left ventricular assist devices. JACC Heart Fail. 2022;10(2):89-100. doi:10.1016/j.jchf.2021.09.008